A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure

Phase 1 Withdrawn 32 enrolled Facet Biotech

RandomizedParallel-groupDouble-blindTreatment

Summary

To determine the maximum tolerated dose (MTD) of ularitide in the treatment of subjects hospitalized with symptomatic acute decompensated heart failure (ADHF).

Timeline

Start: —
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ularitide	Protein / enzyme biologic	—	—

A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure

Summary

Timeline

Drugs

Indications